Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Rhea-AI Summary
Apyx Medical (NASDAQ: APYX), manufacturer of proprietary helium plasma and radiofrequency technology Renuvion®, has scheduled its first quarter fiscal year 2025 financial results release for May 8, 2025, before market open.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (800-717-1738 for domestic, 646-307-1865 for international) using access code 63341, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. The company's products are supported by over 90 clinical publications.
Positive
- None.
Negative
- None.
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
FAQ
When will Apyx Medical (APYX) release Q1 2025 earnings?
How can investors join APYX's Q1 2025 earnings call?
What are Apyx Medical's main products in the medical device market?
How many clinical publications support Apyx Medical's technology?
